1. Antagonists of TNFα for recurrent miscarriages: 2 Illustrative cases
- Author
-
J. Cohen, Arsène Mekinian, Véronique Houfflin-Debarge, Noémie Abisror, Olivier Fain, Kamilla Kolanska, Marie Bornes, and Gilles Kayem
- Subjects
Adult ,Abortion, Habitual ,medicine.medical_specialty ,Anti-Inflammatory Agents ,03 medical and health sciences ,0302 clinical medicine ,Fibrinolytic Agents ,Refractory ,Pregnancy ,Prednisone ,medicine ,Adalimumab ,Humans ,030212 general & internal medicine ,Adverse effect ,030219 obstetrics & reproductive medicine ,Aspirin ,Tumor Necrosis Factor-alpha ,business.industry ,Obstetrics ,Pregnancy Outcome ,Obstetrics and Gynecology ,Hydroxychloroquine ,medicine.disease ,Treatment Outcome ,Reproductive Medicine ,Etiology ,Gestation ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Approximately 1 to 3% of women have recurrent early miscarriages, defined as ≥3 pregnancy losses before 14 weeks of gestation. The immune deregulation and tolerance rupture could be the origin of these miscarriages in at least 30% of these women. Chronic intervillositis of unknown etiology (CIUE) is a rare placental lesion characterized by intrauterine deaths, growth restriction and high recurrence rate. In cases with recurrent obstetrical adverse events and intrauterine deaths, we previously reported the benefit of hydroxychloroquine combination to prednisone. Even few data raised the potential value of TNF antagonists in early recurrent miscarriages, these cases show its potential value in the setting of recurrent refractory chronic intervillositis and unexplained miscarriages.
- Published
- 2019
- Full Text
- View/download PDF